These data suggest that tumor cells resistant to BRAF-i may overexpress ligands recognized by activating NK receptors as a consequence of the MAPK pathway activation, thus becoming more sensitive to NK-mediated lysis. The gene discussed is BRAF; the disease is neoplasm.